Literature DB >> 23143946

Specific genetic polymorphisms of IL10-592 AA and IL10-819 TT genotypes lead to the key role for inducing docetaxel-induced liver injury in breast cancer patients.

Xu Liang1, Jie Zhang, Yulin Zhu, Yuanli Lu, Xinna Zhou, Zheng Wang, Jing Yu, Ying Yan, Lijun Di, Li Che, Hanfang Jiang, Bin Shao, Xiaoli Wang, Huabing Yang, Herbert Kim Lyerly, Jun Ren.   

Abstract

AIM: This study was designed to explore the genetic polymorphism of IL-10 (-1082A/G, -592A/C, -819T/C), TNF-α (-308G/A) with susceptibility to docetaxel-induced liver injury (DILI) in Chinese breast cancer patients.
METHODS: The targeted genetic polymorphisms of IL10-1082G/A, IL10-592A/C, IL10-819T/C, TNF-308G/A from 40 patients with DILI were assayed by matrix-assisted laser desorption/ionization-time of flight of Sequenom.
RESULTS: AA genotype of IL10-592 and TT of IL10-819 significantly increased incidence of DILI (P = 0.005, OR = 3.137). No differences of TNF gene polymorphism between the two groups were seen.
CONCLUSION: The genetic polymorphism of the IL10-592A/C AA genotype and IL10-819T/C TT genotype was predominantly conferred to the incidence of docetaxel-induced liver injury.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23143946     DOI: 10.1007/s12094-012-0936-6

Source DB:  PubMed          Journal:  Clin Transl Oncol        ISSN: 1699-048X            Impact factor:   3.405


  14 in total

1.  Safety of newly approved drugs: implications for prescribing.

Authors:  Robert J Temple; Martin H Himmel
Journal:  JAMA       Date:  2002-05-01       Impact factor: 56.272

2.  A panel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal function.

Authors:  Josef S Ozer; Frank Dieterle; Sean Troth; Elias Perentes; André Cordier; Pablo Verdes; Frank Staedtler; Andreas Mahl; Olivier Grenet; Daniel R Roth; Daniel Wahl; François Legay; Daniel Holder; Zoltan Erdos; Katerina Vlasakova; Hong Jin; Yan Yu; Nagaraja Muniappa; Tom Forest; Holly K Clouse; Spencer Reynolds; Wendy J Bailey; Douglas T Thudium; Michael J Topper; Thomas R Skopek; Joseph F Sina; Warren E Glaab; Jacky Vonderscher; Gérard Maurer; Salah-Dine Chibout; Frank D Sistare; David L Gerhold
Journal:  Nat Biotechnol       Date:  2010-05       Impact factor: 54.908

3.  Ethnicity greatly influences cytokine gene polymorphism distribution.

Authors:  Steven C Hoffmann; Eran M Stanley; E Darrin Cox; Barbara S DiMercurio; Deloris E Koziol; David M Harlan; Allan D Kirk; Patrick J Blair
Journal:  Am J Transplant       Date:  2002-07       Impact factor: 8.086

4.  A simple salting out procedure for extracting DNA from human nucleated cells.

Authors:  S A Miller; D D Dykes; H F Polesky
Journal:  Nucleic Acids Res       Date:  1988-02-11       Impact factor: 16.971

5.  Non-genetic risk factors and predicting efficacy for docetaxel--drug-induced liver injury among metastatic breast cancer patients.

Authors:  Zheng Wang; Xu Liang; Jing Yu; Xiaohui Zheng; Yulin Zhu; Ying Yan; Ningning Dong; Lijun Di; Guohong Song; Xinna Zhou; Xiaoli Wang; Huabing Yang; Jun Ren; Herbert Kim Lyerly
Journal:  J Gastroenterol Hepatol       Date:  2012-08       Impact factor: 4.029

6.  Reduced severity of liver ischemia/reperfusion injury following hepatic resection in humans is associated with enhanced intrahepatic expression of Th2 cytokines.

Authors:  Carlo Pulitanò; Giovanni Sitia; Luca Aldrighetti; Renato Finazzi; Marcella Arru; Marco Catena; Luca G Guidotti; Gianfranco Ferla
Journal:  Hepatol Res       Date:  2006-07-10       Impact factor: 4.288

7.  Predominant role of tumor necrosis factor-alpha in human monocyte IL-10 synthesis.

Authors:  C Wanidworanun; W Strober
Journal:  J Immunol       Date:  1993-12-15       Impact factor: 5.422

8.  Analysis of IL-10, IL-4 and TNF-alpha polymorphisms in drug-induced liver injury (DILI) and its outcome.

Authors:  Ketevan Pachkoria; M Isabel Lucena; Esperanza Crespo; Francisco Ruiz-Cabello; Susana Lopez-Ortega; M A Carmen Fernandez; Manuel Romero-Gomez; Ana Madrazo; Jose Antonio Durán; Ana Malcon de Dios; Yolanda Borraz; Jose Maria Navarro; Raúl J Andrade
Journal:  J Hepatol       Date:  2008-04-22       Impact factor: 25.083

9.  Hepatic adducts, circulating antibodies, and cytokine polymorphisms in patients with diclofenac hepatotoxicity.

Authors:  Guruprasad P Aithal; Lesley Ramsay; Ann K Daly; Nhareet Sonchit; Julian B S Leathart; Graeme Alexander; J Gerald Kenna; John Caldwell; Christopher P Day
Journal:  Hepatology       Date:  2004-05       Impact factor: 17.425

10.  Interleukin-10 and interferon-gamma gene polymorphisms in patients with nasopharyngeal carcinoma.

Authors:  K Farhat; E Hassen; S Gabbouj; N Bouaouina; L Chouchane
Journal:  Int J Immunogenet       Date:  2008-02-28       Impact factor: 1.466

View more
  8 in total

Review 1.  Role of pharmacogenomics in T-cell hypersensitivity drug reactions.

Authors:  Rebecca J Hertzman; Pooja Deshpande; Andrew Gibson; Elizabeth J Phillips
Journal:  Curr Opin Allergy Clin Immunol       Date:  2021-08-01

2.  Analysis of IL-6, STAT3 and HSPA1L gene polymorphisms in anti-tuberculosis drug-induced hepatitis in a nested case-control study.

Authors:  Jing Wang; Ru Chen; Shaowen Tang; Xiaozhen Lv; Shanshan Wu; Yuan Zhang; Yinyin Xia; Pei Gao; Dehua Tu; Dafang Chen; Siyan Zhan
Journal:  PLoS One       Date:  2015-03-19       Impact factor: 3.240

3.  Association Analysis of IL10, TNF-α, and IL23R-IL12RB2 SNPs with Behçet's Disease Risk in Western Algeria.

Authors:  Ouahiba Khaib Dit Naib; Mourad Aribi; Aicha Idder; Amel Chiali; Hakim Sairi; Isabelle Touitou; Gérard Lefranc; Mouna Barat-Houari
Journal:  Front Immunol       Date:  2013-10-21       Impact factor: 7.561

4.  Association of three promoter polymorphisms in interleukin-10 gene with cancer susceptibility in the Chinese population: a meta-analysis.

Authors:  Ping Wang; Junling An; Yanfeng Zhu; Xuedong Wan; Hongzhen Zhang; Shoumin Xi; Sanqiang Li
Journal:  Oncotarget       Date:  2017-05-26

5.  [Expert panel consensus statement on prevention and standardized treatment of drug-induced liver injury in patients with blood diseases (2016)].

Authors: 
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2016-06-14

Review 6.  Genomic Risk Factors Driving Immune-Mediated Delayed Drug Hypersensitivity Reactions.

Authors:  Yueran Li; Pooja Deshpande; Rebecca J Hertzman; Amy M Palubinsky; Andrew Gibson; Elizabeth J Phillips
Journal:  Front Genet       Date:  2021-04-16       Impact factor: 4.599

7.  Zafirlukast ameliorates Docetaxel-induced activation of NOD-like receptor protein 3 (NLRP3) inflammasome, mediated by sirtuin1 (SIRT1) in hepatocytes.

Authors:  Ziyi Guo; Xunjin Zeng; Yu Zheng
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

8.  ILs-3, 6 and 11 increase, but ILs-10 and 24 decrease stemness of human prostate cancer cells in vitro.

Authors:  Dandan Yu; Yali Zhong; Xiaoran Li; Yaqing Li; Xiaoli Li; Jing Cao; Huijie Fan; Yuan Yuan; Zhenyu Ji; Baoping Qiao; Jian-Guo Wen; Mingzhi Zhang; Gunnar Kvalheim; Jahn M Nesland; Zhenhe Suo
Journal:  Oncotarget       Date:  2015-12-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.